NCT07658430 · NOT YET RECRUITING
Deep Cervical Lymphovenous Anastomosis for Moderate Alzheimer's Disease
This trial is testing a surgical procedure called deep cervical lymphovenous anastomosis, or LVA, which connects lymphatic vessels in the neck to nearby veins. The idea is that this might help the brain drain waste products, including amyloid and tau proteins linked to Alzheimer's. Researchers want to know whether it improves cognition and clears those proteins compared to standard care alone. This is a Phase NA randomized controlled trial, meaning it is evaluating both safety and effectiveness in a real patient population.
You may qualify if
- Aged 50 to 80 years old, male or female.
- Clinically diagnosed with moderate probable Alzheimer's disease according to the NIA-AA criteria.
- Baseline Mini-Mental State Examination (MMSE) score between 10 and 20 points.
- Clinical cognitive decline duration of at least 6 months.
- Stable routine anti-dementia drug treatment for more than 6 months without obvious clinical improvement.
- Able to complete neuropsychological scale assessments, blood biomarker detection and Aβ-PET examination.
- Have a reliable caregiver who can accompany follow-up visits and assist in completing evaluations.
- The participant or legal surrogate voluntarily signs the written informed consent.
You're excluded if
- Severe cardiac, hepatic, renal, respiratory or hematopoietic system dysfunction unable to tolerate surgery or anesthesia.
- A history of intracranial surgery, severe craniocerebral trauma, stroke, brain tumor or other central nervous system diseases.
- Other types of dementia, including vascular dementia, frontotemporal dementia, Lewy body dementia, or mixed dementia.
- Psychiatric disorders requiring long-term medication that may affect cognitive assessment results.
- Contraindications for PET imaging or contrast agent allergy.
- Active infection, malignant tumor or severe wasting disease.
- Pregnancy or breastfeeding status.
- Participation in other interventional clinical trials within 3 months before enrollment.
- Poor compliance or inability to complete scheduled follow-up.
- Any other condition judged inappropriate for enrollment by the investigator.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-06-22